in Pancreatic Carcinoma Patients T Cell Immunity Is Impaired + Antiviral CD4 Carcinoembryonic Antigen-Specific but Not

Pancreatic carcinoma is a very aggressive disease with dismal prognosis. Although evidences for tumor-specific T cell immunity exist, factors related to tumor microenvironment and the presence of immunosuppressive cytokines in patients’ sera have been related to its aggressive behavior. Carcinoembryonic Ag (CEA) is overexpressed in 80–90% of pancreatic carcinomas and contains epitopes recognized by CD4 (cid:1) T cells. The aim of this study was to evaluate the extent of cancer-immune surveillance and immune suppression in pancreatic carcinoma patients by comparing the anti-CEA and antiviral CD4 (cid:1) T cell immunity. CD4 (cid:1) T cells from 23 normal donors and 44 patients undergoing surgical resection were tested for recognition of peptides corresponding to CEA and viral naturally processed promiscuous epitopes by proliferation and cytokine release assays. Anti-CEA CD4 (cid:1) T cell immunity was present in a significantly higher number of normal donors than pancreatic cancer patients. Importantly, whereas CD4 (cid:1) T cells from normal donors produced mainly GM-CSF and IFN- (cid:2) , CD4 (cid:1) T cells from the patients produced mainly IL-5, demonstrating a skew toward a Th2 type. On the contrary, the extent of antiviral CD4 (cid:1) T cell immunity was comparable between the two groups and showed a Th1 type. The immunohistochemical analysis of tumor-infiltrating lymphocytes showed a significantly higher number of GATA-3 (cid:1) compared with T-bet (cid:1) lymphoid cells, supporting a Th2 skew also at the tumor site. Collectively, these results demonstrate that Th2-immune deviation in pancreatic cancer is not generalized but tumor related and suggests that the skew might be possibly due to factor(s) present at the tumor site. The Journal of Immunology, 2008, 181: 6595–6603.

[1]  T. Nakayama,et al.  Initiation and maintenance of Th2 cell identity. , 2008, Current opinion in immunology.

[2]  M. McGeachy,et al.  Review Th17 Cell Differentiation: the Long and Winding Road , 2022 .

[3]  R. Longhi,et al.  Endosomal proteases influence the repertoire of MAGE-A3 epitopes recognized in vivo by CD4+ T cells. , 2008, Cancer research.

[4]  R. Longhi,et al.  IFN-γ Produced by Human Papilloma Virus-18 E6-Specific CD4+ T Cells Predicts the Clinical Outcome after Surgery in Patients with High-Grade Cervical Lesions1 , 2007, The Journal of Immunology.

[5]  C. Pilarsky,et al.  Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. , 2007, Cancer research.

[6]  Sylvia Janetzki,et al.  Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI) , 2007, Cancer Immunology, Immunotherapy.

[7]  Helmut Friess,et al.  Pancreatic cancer microenvironment , 2007, International journal of cancer.

[8]  M. Koch,et al.  Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma. , 2007, Journal of the National Cancer Institute.

[9]  A. Watson,et al.  Different Forms of Helper Tolerance to Carcinoembryonic Antigen: Ignorance and Regulation , 2007, Clinical Cancer Research.

[10]  Q. Yao,et al.  Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. , 2007, Cancer research.

[11]  B. Kyewski,et al.  Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: implications for self-tolerance and tumor therapy. , 2007, Cancer research.

[12]  M. Roncarolo,et al.  Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. , 2007, International immunology.

[13]  A. Scarpa,et al.  Cooperative Induction of a Tolerogenic Dendritic Cell Phenotype by Cytokines Secreted by Pancreatic Carcinoma Cells1 , 2006, The Journal of Immunology.

[14]  M. Bevan,et al.  T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. , 2006, Immunity.

[15]  G. Melloni,et al.  Identification of Novel Subdominant Epitopes on the Carcinoembryonic Antigen Recognized by CD4+ T Cells of Lung Cancer Patients1 , 2006, The Journal of Immunology.

[16]  M. Pfreundschuh,et al.  Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  H. Friess,et al.  Aberrant Gata-3 Expression in Human Pancreatic Cancer , 2006, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[18]  M. Büchler,et al.  High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. , 2005, Cancer research.

[19]  R. Offringa,et al.  Expression of a natural tumor antigen by thymic epithelial cells impairs the tumor-protective CD4+ T-cell repertoire. , 2005, Cancer research.

[20]  T. Wynn.  Fibrotic disease and the TH1/TH2 paradigm , 2004, Nature Reviews Immunology.

[21]  N. Funel,et al.  Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma , 2004, Journal of Clinical Pathology.

[22]  R. Schroers,et al.  Identification of a MHC class-II restricted epitope in carcinoembryonic antigen , 2004, Cancer Immunology, Immunotherapy.

[23]  J. Prieto,et al.  Identification and Characterization of a T-Helper Peptide from Carcinoembryonic Antigen , 2004, Clinical Cancer Research.

[24]  H. Groux,et al.  Specialization in tolerance: innate CD4+CD25+ versus acquired TR1 and TH3 regulatory T cells.1 , 2004, Transplantation.

[25]  R. Longhi,et al.  Coupling Tumor Necrosis Factor-α with αV Integrin Ligands Improves Its Antineoplastic Activity , 2004, Cancer Research.

[26]  R. Longhi,et al.  CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. , 2003, Cancer research.

[27]  J. Finke,et al.  Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. , 2003, Cancer research.

[28]  H. Tanaka,et al.  Specific T-cell immunity against Ki-ras peptides in patients with pancreatic and colorectal cancers , 2003, British Journal of Cancer.

[29]  M. Griffioen,et al.  CD4+ Th2 Cell Recognition of HLA-DR-Restricted Epitopes Derived from CAMEL: A Tumor Antigen Translated in an Alternative Open Reading Frame , 2003, The Journal of Immunology.

[30]  J. Prieto,et al.  Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  J. Kirkwood,et al.  Disease-associated Bias in T Helper Type 1 (Th1)/Th2 CD4+ T Cell Responses Against MAGE-6 in HLA-DRB10401+ Patients With Renal Cell Carcinoma or Melanoma , 2002, The Journal of experimental medicine.

[32]  T. Eberlein,et al.  Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.

[33]  Hiroya Kobayashi,et al.  Inhibition of EBV-Induced Lymphoproliferation by CD4+ T Cells Specific for an MHC Class II Promiscuous Epitope1 , 2002, The Journal of Immunology.

[34]  N. Berinstein.  Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Oka,et al.  Detection of peptide‐specific cytotoxic T‐lymphocyte precursors used for specific immunotherapy of pancreatic cancer , 2002, International journal of cancer.

[36]  B. Longenecker,et al.  MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment , 2001, Glycoconjugate Journal.

[37]  H. Kalthoff,et al.  Systemic and local immunosuppression in pancreatic cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  A. Ohta,et al.  Distinct Role of Antigen-Specific T Helper Type 1 (Th1) and Th2 Cells in Tumor Eradication in Vivo , 1999, The Journal of experimental medicine.

[39]  G Bellone,et al.  Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. , 1999, The American journal of pathology.

[40]  U. Şahin,et al.  Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices , 1999, Nature Biotechnology.

[41]  H. Kalthoff,et al.  Immunological Escape Mechanisms in Pancreatic Carcinoma , 1999, Annals of the New York Academy of Sciences.

[42]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[43]  H. Kalthoff,et al.  Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. , 1998, Cancer research.

[44]  Malfertheiner,et al.  Effector T lymphocyte subsets in human pancreatic cancer: detection of CD8+ CD18+ cells and CD8+ CD103+ cells by multi‐epitope imaging , 1998, Clinical and experimental immunology.

[45]  S. Romagnani,et al.  The Th1/Th2 paradigm. , 1997, Immunology today.

[46]  Kenneth M. Murphy,et al.  Functional diversity of helper T lymphocytes , 1996, Nature.

[47]  D. Byrd,et al.  CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. , 1995, Cancer research.

[48]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[49]  D. Wiley,et al.  Peptide binding to HLA‐DR1: a peptide with most residues substituted to alanine retains MHC binding. , 1990, The EMBO journal.

[50]  J. Fielding,et al.  Demonstration of carcinoembryonic antigen (CEA) expression in normal, chronically inflamed, and malignant pancreatic tissue by immunohistochemistry. , 1986, Journal of clinical pathology.

[51]  T. Wynn.  Fibrotic disease and the T(H)1/T(H)2 paradigm. , 2004, Nature reviews. Immunology.